Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

BACKGROUND: Using a monoclonal antibody with greater affinity for IgE than omalizumab, we examined whether more complete suppression of IgE provided greater pharmacodynamic effects, including suppression of skin prick responses to allergen. OBJECTIVE: To explore the pharmacokinetics, pharmacodynamic...

Descripción completa

Detalles Bibliográficos
Autores principales: Arm, J P, Bottoli, I, Skerjanec, A, Floch, D, Groenewegen, A, Maahs, S, Owen, C E, Jones, I, Lowe, P J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278557/
https://www.ncbi.nlm.nih.gov/pubmed/25200415
http://dx.doi.org/10.1111/cea.12400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278557/
https://www.ncbi.nlm.nih.gov/pubmed/25200415
http://dx.doi.org/10.1111/cea.12400

Ejemplares similares